BioNTech SE (BNTX) Other Non-Current Assets (2018 - 2025)
BioNTech SE (BNTX) posted Other Non-Current Assets of $202.3 million for Q4 2025, down 40.92% on a QoQ basis from $342.4 million in Q3 2025, and down 10.99% year-over-year from $227.3 million in Q4 2024.
BioNTech SE (BNTX) has 7 years of Other Non-Current Assets data on file, last reported at $202.3 million in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 10.99% year-over-year to $202.3 million; the TTM figure through Dec 2025 stood at $202.3 million (down 10.99% YoY), while the FY2025 annual figure was $196.4 million, down 13.61% from the prior year.
- Other Non-Current Assets eased to $202.3 million in Q4 2025, from $342.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $386.9 million in Q2 2024 and bottomed at $49.7 million in Q2 2022.
- A 5-year average of $226.3 million and a median of $231.2 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 364.92% — and 2025, when it tumbled 37.1%.
- Year by year, Other Non-Current Assets stood at $129.7 million in 2021, then rose by 26.46% to $164.0 million in 2022, then jumped by 84.24% to $302.2 million in 2023, then dropped by 24.8% to $227.3 million in 2024, then fell by 10.99% to $202.3 million in 2025.
- The last three Other Non-Current Assets figures came in at $202.3 million (Q4 2025), $342.4 million (Q3 2025), and $243.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | 202.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 202.31 Mn |
| Sep 30, 2025 | 342.42 Mn |
| Jun 30, 2025 | 243.37 Mn |
| Mar 31, 2025 | 246.46 Mn |
| Dec 31, 2024 | 227.29 Mn |
| Sep 30, 2024 | 302.89 Mn |
| Jun 30, 2024 | 386.93 Mn |
| Mar 31, 2024 | 366.10 Mn |
| Dec 31, 2023 | 302.23 Mn |
| Sep 30, 2023 | 311.55 Mn |
| Jun 30, 2023 | 231.18 Mn |
| Mar 31, 2023 | 183.86 Mn |
| Sep 30, 2022 | 164.05 Mn |
| Jun 30, 2022 | 49.72 Mn |
| Mar 31, 2022 | 72.84 Mn |
| Dec 31, 2021 | 129.73 Mn |
| Mar 31, 2021 | 83.95 Mn |
| Dec 31, 2019 | 10.04 Mn |
| Sep 30, 2019 | 10.40 Mn |
| Dec 31, 2018 | 10.46 Mn |